VahatiCor
Santa Clara, California, United States · Biotechnology, Health Care, Medical · 15 employees
VahatiCor is a medtech company dedicated to transforming cardiac care for Coronary Microvascular Dysfunction (CMD). They are focused on developing innovative therapies, particularly the A-FLUX Reducer System®, which aims to enhance myocardial perfusion and relieve symptoms of angina for millions affected by CMD. The company is currently advancing clinical studies and preparing for pivotal trials t
Funding history
- Funding Round — $21.2M — Dec 2025
- Series series b — $23.0M — Nov 2025
Recent signals
- May 18, 2026: VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer
- Dec 04, 2025: Raised $21.2M
- Nov 18, 2025: Raised $23.0M in Series series b
See plans & pricing → Track VahatiCor’s funding, hiring, and signals — with verified contacts — on Fundz.